A valid MOD GRF 1-29 COA provides essential analytical verification, confirming peptide identity, chemical purity, and endotoxin safety thresholds for preclinical laboratory research. Institutional researchers rely on lot-specific documentation to ensure rigorous experimental reproducibility across in vitro and animal models.
A valid MOD GRF 1-29 COA provides essential analytical verification, confirming peptide identity, chemical purity, and endotoxin safety thresholds for preclinical laboratory research. Institutional researchers rely on lot-specific documentation to ensure rigorous experimental reproducibility across in vitro and animal models.
A Certificate of Analysis (COA) for MOD GRF 1-29 (also designated as CJC-1295 without DAC) serves as the primary standard for verifying reagent identity, purity, and safety prior to laboratory experimentation. Every certified lot must document reverse-phase high-performance liquid chromatography (RP-HPLC) showing absolute purity above 98%, electrospray ionization mass spectrometry (ESI-MS) confirming molecular mass, and chromogenic LAL assays validating low endotoxin thresholds.
Researchers evaluating MOD GRF 1-29 COA documentation should verify that analytical testing was performed by an independent, ISO 17025-accredited facility. PX1 Research supplies comprehensive batch-specific documentation alongside every compound to guarantee complete transparency and reproducibility across preclinical protocols.
MOD GRF 1-29 is a synthetic 29-amino-acid peptide analog corresponding to the N-terminal functional region of endogenous growth-hormone-releasing hormone (GHRH, 1-44). To prevent rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) in vitro and in vivo, specific amino acid substitutions were introduced at positions 2, 8, 15, and 27: D-Alanine at position 2, L-Glutamine at position 8, L-Glycine at position 15, and L-Leucine at position 27. These structural modifications significantly increase metabolic stability while preserving full agonist affinity for the GHRH receptor.
Unlike extended-release GHRH conjugates, MOD GRF 1-29 lacks the Drug Affinity Complex (DAC) maleimido derivative, resulting in a physiological half-life of approximately 30 minutes in animal models. This characteristic allows researchers to study pulsatile somatotroph stimulation rather than baseline continuous receptor saturation. Detailed chemical properties, amino acid sequences, and theoretical molecular weight profiles can be examined within our comprehensive GHRH analogs guide.
A rigorous MOD GRF 1-29 COA requires multi-modal analytical testing to guarantee peptide integrity. Analytical reverse-phase high-performance liquid chromatography (RP-HPLC) isolates the target peptide from synthesis byproducts, truncated sequences, or oxidation states. Peak area integration at a UV detection wavelength of 214 nm confirms baseline purity, with standard research criteria requiring ≥98.0% target area integration.
Mass spectrometry (typically ESI-MS or MALDI-TOF) validates molecular identity by measuring the exact mass-to-charge ratio (m/z) of the ionized peptide. For MOD GRF 1-29 (C33H74N22O10, nominal mass ~3,367.9 Da), observed mass spectrum peaks must match the calculated theoretical mass within strict tolerance limits. Furthermore, Limulus Amebocyte Lysate (LAL) testing measures bacterial endotoxin burden, ensuring levels remain well under standard institutional research cutoffs (<0.1 EU/mg) to prevent non-specific immunological activation in bioassays. Researchers can access detailed quality standards across our research library hub.
PX1 Research enforces strict quality control parameters across our entire inventory. Every batch of lyophilized research peptides is synthesized in GMP-compliant facilities in the United States and subjected to mandatory third-party verification prior to release.
Key quality assurance benchmarks guaranteed by PX1 Research include: • Purity Level: ≥98.0% verified via analytical RP-HPLC. • Molecular Identity: Confirmed via ESI-MS mass spec analysis. • Endotoxin Testing: <0.1 EU/mg verified by chromogenic LAL testing. • Manufacturing Location: USA-based synthesis and formulation. • Batch Traceability: Individual lot numbers matched directly to verifiable COAs. • Rapid Dispatch: Same-day shipping on orders placed Monday–Friday before cutoffs, dispatched directly from fulfillment hubs in CA and AZ.
These standards ensure that laboratories purchasing research peptides receive reagents free from heavy metal contaminants, residual trifluoroacetic acid (TFA) salts beyond allowable limits, or cross-contaminants.
In preclinical endocrine studies, combining a GHRH analog with a selective growth hormone secretagogue receptor (GHSR-1a) agonist provides a powerful model for dual-pathway somatotroph activation. MOD GRF 1-29 acts specifically on the GHRH receptor to initiate cyclic adenosine monophosphate (cAMP) signal transduction. Concurrently, ghrelin mimetic compounds such as Ipamorelin stimulate the GHSR-1a receptor, triggering intracellular calcium release via the phospholipase C pathway.
When administered simultaneously in animal models, these distinct signaling cascades exert a synergistic amplification on pituitary growth hormone release without causing significant elevations in cortisol or prolactin. Researchers examining co-formulated compounds like CJC-1295 & Ipamorelin 10mg frequently analyze dual COAs to confirm precise stoichiometry and total peptide mass per vial.
Understanding the kinetic and pharmacodynamic differences among secretagogue classes is critical when designing preclinical research protocols. The table and analysis below compare primary GHRH analogs and growth hormone-releasing peptides (GHRPs):
1. MOD GRF 1-29 (CJC-1295 No DAC): Short elimination half-life (~30 minutes), mimicking natural physiological pulsatile GHRH signaling. 2. CJC-1295 DAC: Covalently binds serum albumin via a maleimidopropionate linker, extending plasma half-life to several days and resulting in continuous, non-pulsatile GHRH pathway activation. 3. GHRP-2: A potent GHSR agonist that elicits strong growth hormone pulses but may produce moderate secondary elevations in ACTH and prolactin compared to highly selective agonists like Ipamorelin.
Selecting the appropriate compound depends on whether the experimental design requires sharp, acute GH spikes or sustained, continuous baseline elevation for tissue repair and cell proliferation assays.
Preclinical studies indicate that MOD GRF 1-29 activates the anterior pituitary somatotrophs, promoting transcription and secretion of growth hormone (GH). Elevated circulating GH subsequently stimulates hepatic expression of insulin-like growth factor 1 (IGF-1), a primary mediator of cell growth, protein synthesis, and extracellular matrix remodeling.
In vitro models and rodent tissue assays demonstrate that sustained activation of the GHRH/IGF-1 axis promotes nitrogen retention, enhances fibroblast proliferation, and accelerates satellite cell activation in skeletal muscle tissue. Furthermore, preclinical models suggest potential applications in cartilage matrix repair and metabolic lipid oxidation studies, providing a broad foundational scope for endocrine research.
To maintain structural stability and prevent peptide degradation, strict laboratory handling procedures must be observed upon receipt of lyophilized MOD GRF 1-29 vials. Reconstitution should be performed using bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on downstream cell culture or bioassay compatibility.
Recommended handling guidelines: • Reconstitution: Direct the diluent stream along the glass inner wall of the vial rather than directly onto the lyophilized cake. Gently swirl the vial until dissolved; never vortex or shake vigorously. • Temperature Stability: Lyophilized powder remains stable at -20°C for up to 24 months. Reconstituted solutions should be stored at 2°C to 8°C and evaluated within 30 days. • Aliquot Management: To avoid damaging freeze-thaw cycles, reconstitute and divide into single-use microcentrifuge aliquots frozen at -80°C for long-term study series.
For complete details on bulk requisition, volume discounts, and laboratory account provisioning, visit our wholesale lab portal.
What is a mod grf 1-29 coa?
A MOD GRF 1-29 COA (Certificate of Analysis) is an official analytical document provided by an independent laboratory verifying the identity, chemical purity (via RP-HPLC), molecular weight (via ESI-MS), and endotoxin levels of a specific batch of MOD GRF 1-29 peptide.
What purity level should be expected on a MOD GRF 1-29 COA?
Institutional laboratory standards require a minimum purity threshold of 98.0% as determined by RP-HPLC peak area integration. High purity ensures experimental reproducibility and eliminates interference from truncated sequences or synthesis impurities.
How does mass spectrometry verify MOD GRF 1-29 identity?
Mass spectrometry (such as ESI-MS) measures the mass-to-charge ratio of the ionized peptide. The resulting mass spectrum must match the theoretical molecular weight of MOD GRF 1-29 (approximately 3,367.9 Da) to confirm identity.
What is the structural difference between MOD GRF 1-29 and CJC-1295 DAC?
MOD GRF 1-29 consists of 29 amino acids with four stabilizing substitutions (positions 2, 8, 15, and 27) but lacks the Drug Affinity Complex (DAC). CJC-1295 DAC contains an added maleimide derivative that binds to serum albumin, extending its biological half-life from ~30 minutes to several days.
Why is endotoxin testing critical on a MOD GRF 1-29 COA?
Endotoxin testing via chromogenic LAL assay ensures bacterial lipopolysaccharides (LPS) are below strict thresholds (<0.1 EU/mg). High endotoxin levels can induce non-specific inflammatory responses in cellular assays or animal models, confounding experimental data.
Are PX1 Research COAs lot-specific and third-party verified?
Yes. Every single batch of MOD GRF 1-29 from PX1 Research is tested by an independent, ISO 17025-accredited testing laboratory, and individual lot-matched COAs are fully accessible for institutional verification.
How should reconstituted MOD GRF 1-29 be stored in the lab?
Once reconstituted with bacteriostatic water, liquid aliquots should be refrigerated at 2°C–8°C for short-term use (up to 30 days) or stored at -80°C for extended periods to prevent hydrolytic degradation.
What is the shipping turnaround time for MOD GRF 1-29 orders?
PX1 Research dispatches orders same-day when placed Monday through Friday prior to daily cutoff times. All orders ship directly from fulfillment facilities located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.